RxDoctor Payments Data

John Martinez, MD

Nephrology · Branson, MONPI 1154352417

Payments from drug & device makers

$1,596in general payments, 2019–2025

Across 59 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$350
  • Cook Medical LLC$277
  • Mallinckrodt Enterprises LLC$146
  • Travere Therapeutics, Inc.$123
  • AstraZeneca$91
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$87
  • plus $523 from 16 others

What the payments were for

  • Travel & lodging$19512%
  • Food & beverage$1,22577%
  • Education$17611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,596 in reported general payments places this provider in the 60th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$195,683
Medicare patients
445
Services billed
2,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cinacalcet Hcl24$31,828
FarxigaDapagliflozin Propanediol14$11,994
ProsolParenteral Amino Acid 20% No.136$7,630
Sevelamer Carbonate30$5,193
ClinisolParenteral Amino Acid 15% No.521$3,561
Nifedipine ErNifedipine48$1,515
Torsemide64$1,435
Irbesartan84$723
Valsartan18$627
Amlodipine Besylate92$499
Losartan Potassium57$480
Tamsulosin Hcl45$448
Allopurinol59$436
Carvedilol61$388
Labetalol Hcl13$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$91$11,99414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 253 nephrology providers in Missouri.

Other nephrology in Branson

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →